Anixa Biosciences (ANIX) said Tuesday it has entered into a letter of intent with Verdi Solutions to develop artificial intelligence-guided peptide vaccines, tailored to individual cancer patients.
Under the letter of intent, Anixa has a six-month exclusive right to finalize a transaction for the research, development, and commercialization of Verdi's cancer vaccines.
Anixa and Verdi are targeting to start clinical trials for personalized vaccines in the US, the biotechnology company said.
Verdi is also developing off-the-shelf cancer vaccines, combined with companion diagnostics, Anixa said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.